Immunic
Yahoo Finance • 6 hours ago
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story
Yahoo Finance • 3 months ago
Immunic board authorizes up to 35 million stock appreciation rights for employees
Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $80 million, announced that on Monday its board of directors authorized grants of up to 35,000,000 stock appreciation rig... Full story
Yahoo Finance • 3 months ago
Immunic reports low disability worsening rates in MS drug trial
NEW YORK - Immunic, Inc. (NASDAQ:IMUX) announced Tuesday that 92.3% of patients treated with its experimental multiple sclerosis drug vidofludimus calcium remained free of 12-week confirmed disability worsening after 144 weeks of treatment... Full story
Yahoo Finance • 2 years ago
After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate
Immunic, Inc (NASDAQ: IMUX) reported data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838), in patients with moderate-to-severe ulcerative colitis (UC). Data showed a dose-linear incr... Full story
Yahoo Finance • 3 years ago
Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript
Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript February 23, 2023 Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Com... Full story
Yahoo Finance • 3 years ago
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
– Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Secon... Full story
Yahoo Finance • 3 years ago
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune... Full story
